Cleared Traditional

K250377 - Flowflex Plus COVID-19 + Flu A/B Home Test (FDA 510(k) Clearance)

May 2025
Decision
89d
Days
Class 2
Risk

K250377 is an FDA 510(k) clearance for the Flowflex Plus COVID-19 + Flu A/B Home Test. This device is classified as a Multi-analyte Respiratory Virus Antigen Detection Test (Class II - Special Controls, product code SCA).

Submitted by ACON Laboratories, Inc. (San Diego, US). The FDA issued a Cleared decision on May 10, 2025, 89 days after receiving the submission on February 10, 2025.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3987. A Multi-analyte Respiratory Virus Antigen Detection Test Is An In Vitro Diagnostic Device Intended For The Detection And/or Differentiation Of Respiratory Viruses Directly From Respiratory Clinical Specimens. The Device Is Intended To Be Performed At The Site Of Sample Collection, Does Not Involve Sample Storage And/or Transport..

Submission Details

510(k) Number K250377 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 10, 2025
Decision Date May 10, 2025
Days to Decision 89 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Statement

Device Classification

Product Code SCA — Multi-analyte Respiratory Virus Antigen Detection Test
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3987
Definition A Multi-analyte Respiratory Virus Antigen Detection Test Is An In Vitro Diagnostic Device Intended For The Detection And/or Differentiation Of Respiratory Viruses Directly From Respiratory Clinical Specimens. The Device Is Intended To Be Performed At The Site Of Sample Collection, Does Not Involve Sample Storage And/or Transport.